AGLOW ACNE SOLUTION - CLINICAL STUDY
Clinical study on acne-inflammation
The safety and efficacy of twice-daily use of AGLOW Acne Solution (Deep Pore Cleanser and Acne Spot Corrector) was assessed in a 6-week open-label clinical study in 25 male and female volunteers, ages 12-35, having mild to moderate acne vulgaris. Efficacy was measured as a function of mean change from baseline in number of inflammatory and non-inflammatory acne lesions at weeks 1, 2, 4 and 6 as shown in Table 1.
Visual improvements in acne were demonstrated using standardized digital photography using the Canfield Visia CR photography system as shown in figure 1.
Figure 1:
(A) Inflammatory acne lesions before and one week after twice-daily application of AGLOW Acne Solution.
(B) Inflammatory acne lesions before and six weeks after twice-daily application of AGLOW Acne Solution.
The tolerability of the AGLOW Acne Solution was assessed by a trained technician using a 4-point grading scale to measure the severity of erythema, dryness and edema in the facial skin of study volunteers, as shown in Figure 2, throughout the study.
CONCLUSION
The results of this clinical study indicate that twice-daily use of the AGLOW Acne Solution was well-tolerated by all study volunteers and that its onset of action is rapid, capable of producing over 50% reduction in inflammatory acne lesions in as little as 7 days.
published medical release
Medical Release: Clear Acne 3x Faster with AGLOW Acne System, Unveiled at the American Academy of Dermatology Annual Meeting. Published: Feb 28, 2013 @ Westlake Village, Calif.
The AGLOW Acne System combines the power of the Deep Pore Cleanser and Acne Spot Corrector in a two-step system that’s clinically proven to significantly heal acne within days. In fact, a recent study shows that AGLOW clears acne three times faster than the leading over-the-counter and topical acne prescription products on the market today.
New patent-pending PCX Technology available only in AGLOW, which features solubilized bakuchiol and bisabolol that together help salicylic acid attack acne at its source while helping to regulate pore-clogging oil production and to reduce inflammation.
The AGLOW Acne System will be unveiled on the AAD Exhibit floor. Dr. Felipe Jimenez, Chief Scientific Officer, led the development of this new technology and will be on hand to introduce the system and debut the exciting results from a new clinical study.
Accordingly to the study, the AGLOW Acne Solution was tested on 25 volunteers that used the Deep Pore Cleanser and Acne Spot Corrector twice daily over six weeks. After seven days volunteers enjoyed an average 59% reduction in inflammatory acne lesions and a 14%reduction in non-inflammatory acne lesions. After six weeks, 99% of inflammatory and 56% of non-inflammatory acne lesions had been cleared. Plus, unlike benzoyl peroxide- or salicylic acid-based acne products, the results showed that AGLOW does not dry out skin or cause irritation, redness or peeling.
“Even the best acne products can take up to six weeks to work. However, unpleasant side effects from these regimens, including dryness and irritation, often cause patients to stop using the products prior to getting relief from acne. With the launch of AGLOW, patients can now rapidly clear their acne in a safe and effective manner,” says Curtis A. Cluff.
The AGLOW Acne System will be sold through dermatology, cosmetic surgery and medical spa physicians throughout the United States.
